Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Blow for Masimo’s fight with Apple as case against US Customs dismissed

29 April 2026 The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.

Americas

Ligand buys biotech in $739m cash deal with litigation sweetener

28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

More features

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Part I: Ozempic goes generic as Novo’s key patent expires

Emotional Perception: What next for patent holders?

Semaglutide patent battle heats up with new blow for Novo in India

Rooted in rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features